Chronic Spontaneous Urticaria
Conditions
Keywords
CSU
Brief summary
The primary objective of this study is to evaluate the effect of tezepelumab on improvement in the Urticaria Activity Score over 7 days (UAS7).
Interventions
BIOLOGICALTezepelumab Dose 1
Subcutaneous injection.
BIOLOGICALTezepelumab Dose 2
Subcutaneous injection.
BIOLOGICALOmalizumab
Subcutaneous injection.
BIOLOGICALPlacebo
Subcutaneous injection.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Signed informed consent must be obtained prior to participation in the study. * Male and female participants ≥ 18 years and ≤ 80 years of age at the time of screening. * Chronic spontaneous urticaria (CSU) diagnosis for ≥ 6 months at the time of screening. * CSU inadequately controlled by second generation H1-antihistamines (sgAH) at enrollment, as defined by all of the following: * The presence of itch and hives for \>= 6 consecutive weeks at any time prior to screening visit 2 * Failure to respond to an sgAH (up to 4 times the approved dose) * Urticaria Activity Score over 7 days (UAS7) (range 0-42) \>= 16 and Hives Severity Score over 7 days (HSS7) (range 0-21) \>= 8 during the 7 days prior to enrollment * Participant with CSU who discontinued, is intolerant to, or was an inadequate responder to anti-IgE therapies despite being treated with omalizumab 300 mg every 4 weeks (Q4W) for 6 months or higher doses of omalizumab \> 2 months or another anti-IgE therapy. Note: This criterion is only applicable for anti-IgE-experienced participants. * Participant willing and able to complete a daily symptom eDiary for the duration of the study and adhere to the study visit schedules. * Subject must have been on a sgAH at approved or increased doses (up to 4x the approved dose) for treatment of CSU for at least 3 consecutive days immediately prior to the day -14 screening visit (screening visit 2) and must have documented current use on the day of screening visit 1
Exclusion criteria
Disease related, including but not limited to: * Urticaria is solely due to inducible urticaria * Active dermatologic diseases (or conditions) other than chronic urticaria, with urticaria wheals or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to C1 inhibitor deficiency) * Any other active skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (eg, atopic dermatitis, dermatitis herpetiformis, senile pruritus, etc.) * History of a clinically significant infection within 28 days prior to day 1 that, in the opinion of the investigator or medical monitor, might compromise the safety of the participant in the study, interfere with evaluation of the investigational product, or reduce the participants ability to participate in the study. * Evidence of active tuberculosis (TB) (in the opinion of the investigator), either treated or untreated, or a positive purified protein derivative (PPD) or QuantiFERON-TB Gold Plus (QFT-Plus) test for TB during screening. * History of malignancy, except for basal cell carcinoma or in situ carcinoma of the cervix treated with apparent success with curative therapy ≥ 12 months prior to screening or other malignancies treated with apparent success with curative therapy ≥ 5 years prior to screening visit 1. * Subject is unable to complete an electronic patient diary or complete questionnaires, or does not meet the required level of compliance with the eDiary during the 14 days sgAH stabilization period Other medical conditions * History or evidence of severe depression, schizophrenia, previous suicide attempts, or suicidal ideation. Prior/concomitant therapy, including but not limited to: * Treatment with any biologic products (eg, omalizumab, ligelizumab) within 4 months or 5 half-lives (whichever is longer) prior to screening visit 1 * Routine (daily or every other day for 5 or more consecutive days) use of systemic corticosteroids, systemic hydroxychloroquine, methotrexate, cyclosporine A, cyclophosphamide, tacrolimus, azathioprine, and mycophenolate mofetil within 30 days prior to screening visit 1. * Major surgery within 8 weeks prior to screening visit 1 or planned inpatient surgery or hospitalization during the study period. * Receipt of Ig or blood products within 30 days prior to screening visit 1. * Vaccination with a live or attenuated vaccine within 30 days prior to screening visit 1. Receipt of COVID-19 vaccines and inactive/killed vaccinations (eg, inactive influenza) are allowed, provided the vaccinations are not administered within 7 days before or after any study dosing visit. * Known hypersensitivity, including severe hypersensitivity reactions and/or history of anaphylactic shock, to any of the products or components to be administered during dosing or to products of similar chemical classes (ie, to murine, chimeric, or human antibodies.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 | Baseline and Week 16 | The UAS is a CSU-specific patient-reported outcome measure with 2 components: Hives Severity Score (HSS) for number of wheals and an Itch Severity Score (ISS) for itch intensity, and are each scored from 0 (no wheals, no itch) to 3 (\>50 wheals, severe itch) for the previous 24 hours. The HSS and ISS are combined to give a daily UAS ranging from 0 to 6. The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). The least squares mean (LSM) estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UAS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change From Baseline in HSS Over 7 Days (HSS7) at Week 16 | Baseline and Week 16 | The HSS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed the number of wheals, with daily scores ranging from 0 (no wheals) to 3 (\>50 wheals) for the previous 24 hours. The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline HSS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity. |
| Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16 | Week 16 | The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal residual disease in UAS7 was defined as a score ≤ 6 and indicates well-controlled urticaria and a good response to treatment. |
| Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference) | Baseline and Week 16 | The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal important difference in UAS7 was defined as a change from baseline of ≤ -10. |
| Number of Participants With a UAS7 = 0 at Week 16 (Complete Response) | Week 16 | The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). A complete response was defined as UAS7 = 0 at Week 16. |
| Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution) | Week 16 | The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). An ISS7 = 0 indicates a complete resolution of itch. |
| Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference) | Baseline and Week 16 | The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). Minimal important difference in ISS7 was defined as a change from baseline of ≤ -5. |
| Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution) | Week 16 | The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). An HSS7 = 0 indicates a complete resolution of hives. |
| Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference) | Baseline and Week 16 | The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). Minimal important difference in HSS7 was defined as a change from baseline of ≤ -5.5. |
| Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16 | Baseline and Week 16 | The SIS is part of the Urticaria Patient Daily Diary and was assessed by the participant using the electronic diary once daily in the morning. Participants scored sleep interference on a scale of 0 (no interference) to 3 (substantial, woke up often, severe interference with sleep). The SIS7 was a sum of the daily scores over 7 days ranging from 0 to 21. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SIS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep interference. |
| Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16 | Baseline and Week 16 | The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of the 3 daily sleep quality items over 7 days, ranged from 0 (good quality sleep) to 63 (poor quality sleep). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of SQS, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality. |
| Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16 | Baseline and Week 16 | The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of average daily Q1 - Q3 score was generated by averaging 3 daily sleep quality items and then summing the daily average over 7 days with a score ranging from 0 (good quality sleep) to 21 (poor quality sleep) (sum of the average daily Q1 - Q3). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of average daily Q1 - Q3, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality. |
| Change From Baseline in ISS Over 7 Days (ISS7) at Week 16 | Baseline and Week 16 | The ISS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed itch intensity, with daily scores ranging from 0 (no itch) to 3 (severe itch) for the previous 24 hours. The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline ISS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity. |
| Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16 | Baseline and Week 16 | The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Negative changes from baseline indicate an improvement in angioedema activity. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AAS7, treatment, study week and the interaction between treatment and study week. |
| Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free) | Baseline to Week 16 | The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Angioedema occurrence free was defined as AAS7 = 0. |
| Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16 | Baseline and Week 16 | The CU-Q2oL is a 23-item, self-reported urticaria-specific measure to evaluate 6 dimensions of quality of life (QoL): pruritus, impact on life activities, sleep problems, limitations, looks, and swelling. The total score is transformed to a linear scale of 0 to 100 with a higher CU-Q2oL score indicating a higher QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline CU-Q2oL score, treatment, study week and the interaction between treatment and study week. |
| Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | Baseline and Week 16 | The DLQI is a 10-item, participant-completed, health-related QoL assessment with content specific to those with dermatology conditions. The DLQI evaluates participant perceptions including dermatology-related symptoms and feelings, impacts on daily activities, leisure, work or school, personal relationships, and side effects of treatment. The recall period was 1 week. The DLQI total score ranges from 0 to 30 with a higher score indicating a greater QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline DLQI score, treatment, study week and the interaction between treatment and study week. |
| Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16 | Baseline and Week 16 | The AE-QoL is a validated angioedema QoL questionnaire for participants with angioedema. It consists of 17 questions evaluating 4 domains including functioning, fatigue/mood, fear/shame, and food with a recall period of 4 weeks. The total score is transformed to a linear scale ranging from 0 to 100, with a higher score indicating a worse impairment in QoL. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AE-QoL score, treatment, study week and the interaction between treatment and study week. |
| Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16 | Baseline and Week 16 | The AECT is a patient-reported outcome measure to evaluate disease control in the domains of signs and symptoms, QoL, anxiety/fear, and effectiveness of therapy. The total AECT score ranges from 0 to 16, with higher scores indicating well-controlled disease. A positive change from baseline indicates an improvement in angioedema control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AECT score, treatment, study week and the interaction between treatment and study week. |
| Number of Participants With an AECT Score = 16 at Week 16 (Complete Control) | Baseline and Week 16 | The total AECT score ranges from 0 to 16, with higher scores indicating better controlled disease. Complete control was defined as AECT score = 16. |
| Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Baseline and Week 16 | The WPAI-CU is a questionnaire that assesses the impact of an intervention on work productivity, evaluating 4 areas including absenteeism, presenteeism, work productivity loss, and activity impairment over the past 7 days. Each of the areas is scored separately as a percentage, ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity. A negative change from baseline indicates an improvement. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline WPAI-CU score, treatment, study week and the interaction between treatment and study week. |
| Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16 | Baseline to Week 16 | Participants recorded any need of sgAH rescue medication in their daily electronic diary. |
| Serum Concentration of Tezepelumab | Week 1 pre-dose, Weeks 2, 4, 8, 12, 16, 24, and 32 | The lower limit of quantification was 10 ng/mL, and values below this limit were set to zero. |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Day 1 Week 1 to Week 32, up to 32 weeks | An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with study treatment. TEAEs were AEs that started on or after the first dose of investigational product up to the end of study (Week 32). A serious AE (SAE) was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: immediately life-threatening, required hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event. |
| Change From Baseline in Urticaria Control Test (UCT) Score at Week 16 | Baseline and Week 16 | The UCT assesses disease control in participants with CSU through a retrospective validated scoring system, evaluating the physical symptoms of chronic urticaria (itch, hives and/or angioedema) and the effectiveness of treatment over 4 weeks. It consists of 4 questions with 5 answer options, scored from 0 to 4, and the UCT score is the sum of all 4 questions, with total score ranging from 0 (no control) to 16 (complete control). A score of ≥ 12 indicates well-controlled urticaria and a score of ≤ 11 points indicates poor disease control. A positive change from baseline indicates an improvement in disease control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UCT score, treatment, study week and the interaction between treatment and study week. |
Countries
Canada, France, Germany, Greece, Italy, Japan, Poland, South Korea, Spain, United States
Participant flow
Recruitment details
Participants were enrolled at 56 study centers in Japan, Republic of Korea, France, Germany, Greece, Italy, Poland, Spain, Canada, and the United States, and participated from 15 April 2021 to 13 April 2023.
Pre-assignment details
Participants with chronic spontaneous urticaria (CSU) and symptomatic despite treatment with second generation H1-antihistamines (sgAH) were randomized based on if they were previously treated with anti-immunoglobulin E (IgE) therapies or were anti-IgE naïve.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants with and without previous anti-IgE therapy experience were randomized to receive placebo SC Q2W for 16 weeks.
Participants maintained a stable dose of sgAH as background medication from screening Visit 2 (Day -14) to the end of the Safety Follow-up Period (up to Week 32). | 48 |
| Omalizumab 300 mg SC Q4W Participants without previous anti-IgE experience were randomized to receive omalizumab 300 mg SC Q4W for 16 weeks. Participants received placebo SC at intervening study visits to ensure all participants received an injection Q2W.
Participants maintained a stable dose of sgAH as background medication from screening Visit 2 (Day -14) to the end of the Safety Follow-up Period (up to Week 32). | 31 |
| Tezepelumab 210 mg SC Q4W Participants with and without previous anti-IgE therapy experience were randomized to receive tezepelumab 210 mg SC Q4W for 16 weeks. Participants received placebo SC at intervening study visits to ensure all participants received an injection Q2W.
Participants maintained a stable dose of sgAH as background medication from screening Visit 2 (Day -14) to the end of the Safety Follow-up Period (up to Week 32). | 52 |
| Tezepelumab 420 mg SC Q2W Participants with and without previous anti-IgE therapy experience were randomized to receive tezepelumab 420 mg SC Q2W for 16 weeks.
Participants maintained a stable dose of sgAH as background medication from screening Visit 2 (Day -14) to the end of the Safety Follow-up Period (up to Week 32). | 52 |
| Total | 183 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Decision by sponsor | 0 | 1 | 0 | 0 |
| Overall Study | Lost to Follow-up | 1 | 0 | 2 | 2 |
| Overall Study | Protocol specified criteria | 0 | 0 | 2 | 1 |
| Overall Study | Withdrawal by Subject | 4 | 1 | 3 | 1 |
Baseline characteristics
| Characteristic | Placebo | Omalizumab 300 mg SC Q4W | Tezepelumab 210 mg SC Q4W | Tezepelumab 420 mg SC Q2W | Total |
|---|---|---|---|---|---|
| Age, Continuous | 42.8 years STANDARD_DEVIATION 15.2 | 39.8 years STANDARD_DEVIATION 13.1 | 45.0 years STANDARD_DEVIATION 14.7 | 42.9 years STANDARD_DEVIATION 14.5 | 42.9 years STANDARD_DEVIATION 14.5 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 3 Participants | 2 Participants | 3 Participants | 6 Participants | 14 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 45 Participants | 29 Participants | 49 Participants | 46 Participants | 169 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Asian | 18 Participants | 12 Participants | 16 Participants | 14 Participants | 60 Participants |
| Race/Ethnicity, Customized Black or African American | 1 Participants | 2 Participants | 2 Participants | 2 Participants | 7 Participants |
| Race/Ethnicity, Customized Multiple | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized Other | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| Race/Ethnicity, Customized White | 29 Participants | 17 Participants | 34 Participants | 34 Participants | 114 Participants |
| Sex: Female, Male Female | 37 Participants | 23 Participants | 35 Participants | 39 Participants | 134 Participants |
| Sex: Female, Male Male | 11 Participants | 8 Participants | 17 Participants | 13 Participants | 49 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 48 | 0 / 31 | 0 / 52 | 0 / 52 |
| other Total, other adverse events | 14 / 48 | 7 / 31 | 19 / 52 | 20 / 52 |
| serious Total, serious adverse events | 0 / 48 | 1 / 31 | 1 / 52 | 0 / 52 |
Outcome results
Primary
Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16
The UAS is a CSU-specific patient-reported outcome measure with 2 components: Hives Severity Score (HSS) for number of wheals and an Itch Severity Score (ISS) for itch intensity, and are each scored from 0 (no wheals, no itch) to 3 (\>50 wheals, severe itch) for the previous 24 hours. The HSS and ISS are combined to give a daily UAS ranging from 0 to 6. The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). The least squares mean (LSM) estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UAS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
Time frame: Baseline and Week 16
Population: The full analysis set (FAS) included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 | -13.6 score on a scale | Standard Error 1.6 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 | -18.4 score on a scale | Standard Error 2 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 | -13.5 score on a scale | Standard Error 1.6 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in Urticaria Activity Score Over 7 Days (UAS7) at Week 16 | -14.7 score on a scale | Standard Error 1.5 |
p-value: 0.9995% CI: [-4.3, 4.4]Repeated measure model
p-value: 0.695% CI: [-5.4, 3.1]Repeated measure model
Secondary
Change From Baseline in HSS Over 7 Days (HSS7) at Week 16
The HSS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed the number of wheals, with daily scores ranging from 0 (no wheals) to 3 (\>50 wheals) for the previous 24 hours. The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline HSS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in HSS Over 7 Days (HSS7) at Week 16 | -5.8 score on a scale | Standard Error 0.8 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in HSS Over 7 Days (HSS7) at Week 16 | -8.8 score on a scale | Standard Error 1.1 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in HSS Over 7 Days (HSS7) at Week 16 | -6.3 score on a scale | Standard Error 0.8 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in HSS Over 7 Days (HSS7) at Week 16 | -6.7 score on a scale | Standard Error 0.8 |
Secondary
Change From Baseline in ISS Over 7 Days (ISS7) at Week 16
The ISS is a component of the UAS, a CSU-specific patient-reported outcome measure and assessed itch intensity, with daily scores ranging from 0 (no itch) to 3 (severe itch) for the previous 24 hours. The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline ISS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in urticaria activity.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in ISS Over 7 Days (ISS7) at Week 16 | -7.7 score on a scale | Standard Error 0.8 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in ISS Over 7 Days (ISS7) at Week 16 | -9.6 score on a scale | Standard Error 1 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in ISS Over 7 Days (ISS7) at Week 16 | -7.3 score on a scale | Standard Error 0.8 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in ISS Over 7 Days (ISS7) at Week 16 | -8.0 score on a scale | Standard Error 0.8 |
Secondary
Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16
The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of average daily Q1 - Q3 score was generated by averaging 3 daily sleep quality items and then summing the daily average over 7 days with a score ranging from 0 (good quality sleep) to 21 (poor quality sleep) (sum of the average daily Q1 - Q3). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of average daily Q1 - Q3, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16 | -6.5 score on a scale | Standard Error 0.6 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16 | -5.6 score on a scale | Standard Error 0.8 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16 | -6.1 score on a scale | Standard Error 0.6 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in SQS7: Sum of Average Daily Q1 - Q3 at Week 16 | -5.7 score on a scale | Standard Error 0.5 |
Secondary
Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16
The AECT is a patient-reported outcome measure to evaluate disease control in the domains of signs and symptoms, QoL, anxiety/fear, and effectiveness of therapy. The total AECT score ranges from 0 to 16, with higher scores indicating well-controlled disease. A positive change from baseline indicates an improvement in angioedema control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AECT score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with angioedema presence at baseline and at least 1 non-missing AECT record were included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16 | 4.2 score on a scale | Standard Error 1.2 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16 | 3.9 score on a scale | Standard Error 2.2 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16 | 4.6 score on a scale | Standard Error 1.3 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Angioedema Control Test (AECT) Score at Week 16 | 2.3 score on a scale | Standard Error 1.5 |
Secondary
Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16
The AE-QoL is a validated angioedema QoL questionnaire for participants with angioedema. It consists of 17 questions evaluating 4 domains including functioning, fatigue/mood, fear/shame, and food with a recall period of 4 weeks. The total score is transformed to a linear scale ranging from 0 to 100, with a higher score indicating a worse impairment in QoL. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AE-QoL score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with angioedema presence at baseline and at least 1 non-missing AE-QoL record were included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16 | -29.2 score on a scale | Standard Error 6 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16 | -24.1 score on a scale | Standard Error 10.9 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16 | -24.6 score on a scale | Standard Error 6.4 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Angioedema Quality of Life Questionnaire (AE-QoL) at Week 16 | -13.1 score on a scale | Standard Error 7.4 |
Secondary
Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16
The CU-Q2oL is a 23-item, self-reported urticaria-specific measure to evaluate 6 dimensions of quality of life (QoL): pruritus, impact on life activities, sleep problems, limitations, looks, and swelling. The total score is transformed to a linear scale of 0 to 100 with a higher CU-Q2oL score indicating a higher QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline CU-Q2oL score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16 | -19.6 score on a scale | Standard Error 2.1 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16 | -19.8 score on a scale | Standard Error 2.8 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16 | -19.3 score on a scale | Standard Error 2.2 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL) at Week 16 | -18.7 score on a scale | Standard Error 2.1 |
Secondary
Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16
The DLQI is a 10-item, participant-completed, health-related QoL assessment with content specific to those with dermatology conditions. The DLQI evaluates participant perceptions including dermatology-related symptoms and feelings, impacts on daily activities, leisure, work or school, personal relationships, and side effects of treatment. The recall period was 1 week. The DLQI total score ranges from 0 to 30 with a higher score indicating a greater QoL impairment. A negative change from baseline indicates an improvement in QoL. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline DLQI score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | -7.4 score on a scale | Standard Error 0.9 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | -7.3 score on a scale | Standard Error 1.2 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | -7.0 score on a scale | Standard Error 0.9 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Dermatology Life Quality Index (DLQI) at Week 16 | -7.0 score on a scale | Standard Error 0.9 |
Secondary
Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16
The WPAI-CU is a questionnaire that assesses the impact of an intervention on work productivity, evaluating 4 areas including absenteeism, presenteeism, work productivity loss, and activity impairment over the past 7 days. Each of the areas is scored separately as a percentage, ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity. A negative change from baseline indicates an improvement. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline WPAI-CU score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data were included for each question.
| Arm | Measure | Group | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Activity impairment | -28.5 score on a scale | Standard Error 4.2 |
| Placebo | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Absenteeism | -4.7 score on a scale | Standard Error 2.5 |
| Placebo | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Work productivity loss | -20.0 score on a scale | Standard Error 5.4 |
| Placebo | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Presenteeism | -19.9 score on a scale | Standard Error 5.2 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Absenteeism | 0.3 score on a scale | Standard Error 3 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Work productivity loss | -13.3 score on a scale | Standard Error 6.7 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Presenteeism | -18.3 score on a scale | Standard Error 6.6 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Activity impairment | -30.3 score on a scale | Standard Error 5.6 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Activity impairment | -27.2 score on a scale | Standard Error 4.3 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Absenteeism | -7.5 score on a scale | Standard Error 2.5 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Work productivity loss | -23.5 score on a scale | Standard Error 5.5 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Presenteeism | -20.3 score on a scale | Standard Error 5.3 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Activity impairment | -24.1 score on a scale | Standard Error 4.1 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Absenteeism | -2.3 score on a scale | Standard Error 2.7 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Work productivity loss | -17.5 score on a scale | Standard Error 5.9 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in the Work Productivity and Activity Impairment Questionnaire: Chronic Urticaria (WPAI-CU) Score at Week 16 | Presenteeism | -17.8 score on a scale | Standard Error 5.7 |
Secondary
Change From Baseline in Urticaria Control Test (UCT) Score at Week 16
The UCT assesses disease control in participants with CSU through a retrospective validated scoring system, evaluating the physical symptoms of chronic urticaria (itch, hives and/or angioedema) and the effectiveness of treatment over 4 weeks. It consists of 4 questions with 5 answer options, scored from 0 to 4, and the UCT score is the sum of all 4 questions, with total score ranging from 0 (no control) to 16 (complete control). A score of ≥ 12 indicates well-controlled urticaria and a score of ≤ 11 points indicates poor disease control. A positive change from baseline indicates an improvement in disease control. The LSM estimates are based on the repeated measure model with stratification factor (prior anti-IgE status), baseline UCT score, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Urticaria Control Test (UCT) Score at Week 16 | 4.1 score on a scale | Standard Error 0.6 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in Urticaria Control Test (UCT) Score at Week 16 | 6.3 score on a scale | Standard Error 0.8 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in Urticaria Control Test (UCT) Score at Week 16 | 4.9 score on a scale | Standard Error 0.6 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in Urticaria Control Test (UCT) Score at Week 16 | 5.9 score on a scale | Standard Error 0.6 |
Secondary
Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16
The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Negative changes from baseline indicate an improvement in angioedema activity. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline AAS7, treatment, study week and the interaction between treatment and study week.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16 | -19.0 score on a scale | Standard Error 2.7 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16 | -18.7 score on a scale | Standard Error 3.5 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16 | -20.8 score on a scale | Standard Error 2.7 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in Weekly Angioedema Activity Score (AAS7) at Week 16 | -15.6 score on a scale | Standard Error 2.5 |
Secondary
Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16
The SIS is part of the Urticaria Patient Daily Diary and was assessed by the participant using the electronic diary once daily in the morning. Participants scored sleep interference on a scale of 0 (no interference) to 3 (substantial, woke up often, severe interference with sleep). The SIS7 was a sum of the daily scores over 7 days ranging from 0 to 21. The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SIS7, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep interference.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16 | -8.4 score on a scale | Standard Error 0.7 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16 | -6.5 score on a scale | Standard Error 0.9 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16 | -7.4 score on a scale | Standard Error 0.7 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in Weekly Sleep Interference Score (SIS7) at Week 16 | -7.8 score on a scale | Standard Error 0.7 |
Secondary
Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16
The SQS was assessed by the participant through 3 questions relating to falling asleep (Q1), wakefulness (Q2), and feeling rested in the morning (Q3). The sum of the 3 daily sleep quality items over 7 days, ranged from 0 (good quality sleep) to 63 (poor quality sleep). The LSM estimates were based on the repeated measure model with stratification factor (prior anti-IgE status), baseline SQS7 - sum of SQS, treatment, study week and the interaction between treatment and study week. A negative change from baseline indicates an improvement in sleep quality.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16 | -19.5 score on a scale | Standard Error 1.8 |
| Omalizumab 300 mg SC Q4W | Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16 | -16.7 score on a scale | Standard Error 2.3 |
| Tezepelumab 210 mg SC Q4W | Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16 | -18.3 score on a scale | Standard Error 1.7 |
| Tezepelumab 420 mg SC Q2W | Change From Baseline in Weekly Sleep Quality Score (SQS7): Sum of Daily SQS at Week 16 | -17.1 score on a scale | Standard Error 1.6 |
Secondary
Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16
Participants recorded any need of sgAH rescue medication in their daily electronic diary.
Time frame: Baseline to Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (LEAST_SQUARES_MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16 | 49.5 days | Standard Deviation 39 |
| Omalizumab 300 mg SC Q4W | Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16 | 31.6 days | Standard Deviation 42.7 |
| Tezepelumab 210 mg SC Q4W | Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16 | 46.1 days | Standard Deviation 39.3 |
| Tezepelumab 420 mg SC Q2W | Number of Cumulative Days of sgAH Rescue Medication Use From Baseline to Week 16 | 32.7 days | Standard Deviation 33.4 |
Secondary
Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free)
The AAS is a 5-item patient-reported outcome measure used to determine angioedema activity. Participants retrospectively documented the presence or absence of angioedema in the past 24 hours, and the AAS daily score ranged from 0 to 15 points, assessing 5 key factors when angioedema is present, including duration, physical discomfort, impact on daily activities, impact on appearance, and overall severity). The daily AAS scores are summed for 7 days to form the AAS7 with a range of 0 (not present) to 105 (most severe angioedema activity). Angioedema occurrence free was defined as AAS7 = 0.
Time frame: Baseline to Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Placebo | Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free) | 10.8 weeks | Standard Deviation 5.2 |
| Omalizumab 300 mg SC Q4W | Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free) | 11.3 weeks | Standard Deviation 4.9 |
| Tezepelumab 210 mg SC Q4W | Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free) | 9.9 weeks | Standard Deviation 5.8 |
| Tezepelumab 420 mg SC Q2W | Number of Cumulative Weeks That Participants Achieved AAS7 = 0 at Week 16 (Angioedema Occurrence Free) | 11.5 weeks | Standard Deviation 5.4 |
Secondary
Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference)
The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). Minimal important difference in HSS7 was defined as a change from baseline of ≤ -5.5.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference) | 23 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference) | 19 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference) | 24 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With a Change From Baseline in HSS7 of ≤ -5.5 (Minimal Important Difference) | 31 Participants |
Secondary
Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference)
The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). Minimal important difference in ISS7 was defined as a change from baseline of ≤ -5.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference) | 29 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference) | 20 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference) | 28 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With a Change From Baseline in ISS7 of ≤ -5 (Minimal Important Difference) | 34 Participants |
Secondary
Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference)
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal important difference in UAS7 was defined as a change from baseline of ≤ -10.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference) | 28 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference) | 20 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference) | 27 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With a Change From Baseline in UAS7 of ≤ -10 (Minimal Important Difference) | 32 Participants |
Secondary
Number of Participants With an AECT Score = 16 at Week 16 (Complete Control)
The total AECT score ranges from 0 to 16, with higher scores indicating better controlled disease. Complete control was defined as AECT score = 16.
Time frame: Baseline and Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data at Week 16 and angioedema presence at baseline and at least 1 non-missing AECT record were included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With an AECT Score = 16 at Week 16 (Complete Control) | 3 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With an AECT Score = 16 at Week 16 (Complete Control) | 2 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With an AECT Score = 16 at Week 16 (Complete Control) | 0 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With an AECT Score = 16 at Week 16 (Complete Control) | 1 Participants |
Secondary
Number of Participants With a UAS7 = 0 at Week 16 (Complete Response)
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). A complete response was defined as UAS7 = 0 at Week 16.
Time frame: Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With a UAS7 = 0 at Week 16 (Complete Response) | 4 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With a UAS7 = 0 at Week 16 (Complete Response) | 11 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With a UAS7 = 0 at Week 16 (Complete Response) | 7 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With a UAS7 = 0 at Week 16 (Complete Response) | 5 Participants |
Secondary
Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16
The sum of the daily UAS over a 7-day period provides the UAS7, from 0 (no symptoms) to 42 (severe urticaria). Minimal residual disease in UAS7 was defined as a score ≤ 6 and indicates well-controlled urticaria and a good response to treatment.
Time frame: Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16 | 8 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16 | 14 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16 | 10 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With a UAS7 of ≤ 6 (Minimal Residual Disease) at Week 16 | 13 Participants |
Secondary
Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution)
The sum of daily HSS over a 7-day period provides the HSS7, from 0 (no symptoms) to 21 (severe wheals). An HSS7 = 0 indicates a complete resolution of hives.
Time frame: Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution) | 6 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution) | 11 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution) | 8 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With HSS7 = 0 at Week 16 (Complete Resolution) | 6 Participants |
Secondary
Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution)
The sum of daily ISS over a 7-day period provides the ISS7, from 0 (no symptoms) to 21 (severe itch). An ISS7 = 0 indicates a complete resolution of itch.
Time frame: Week 16
Population: The FAS included all randomized participants who received at least 1 dose of investigational product. Participants with observed data are included.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Placebo | Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution) | 4 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution) | 12 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution) | 7 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With ISS7 = 0 at Week 16 (Complete Resolution) | 9 Participants |
Secondary
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with study treatment. TEAEs were AEs that started on or after the first dose of investigational product up to the end of study (Week 32). A serious AE (SAE) was defined as any untoward medical occurrence that met at least 1 of the following serious criteria: immediately life-threatening, required hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or other medically important serious event.
Time frame: Day 1 Week 1 to Week 32, up to 32 weeks
Population: The safety analysis set consisted of all randomized participants who received at least 1 dose of investigational product.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | TEAEs | 23 Participants |
| Placebo | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | SAEs | 0 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | SAEs | 1 Participants |
| Omalizumab 300 mg SC Q4W | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | TEAEs | 24 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | TEAEs | 29 Participants |
| Tezepelumab 210 mg SC Q4W | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | SAEs | 1 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | TEAEs | 28 Participants |
| Tezepelumab 420 mg SC Q2W | Number of Participants With Treatment-emergent Adverse Events (TEAEs) | SAEs | 0 Participants |
Secondary
Serum Concentration of Tezepelumab
The lower limit of quantification was 10 ng/mL, and values below this limit were set to zero.
Time frame: Week 1 pre-dose, Weeks 2, 4, 8, 12, 16, 24, and 32
Population: The pharmacokinetic analysis set included participants who received tezepelumab and had at least 1 sample with a measurable serum concentration. Participants with data available at each time point are included.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Serum Concentration of Tezepelumab | Week 1 | 0.00 µg/mL | Standard Deviation 0 |
| Placebo | Serum Concentration of Tezepelumab | Week 12 | 24.8 µg/mL | Standard Deviation 9.67 |
| Placebo | Serum Concentration of Tezepelumab | Week 4 | 14.2 µg/mL | Standard Deviation 5.78 |
| Placebo | Serum Concentration of Tezepelumab | Week 16 | 27.1 µg/mL | Standard Deviation 10.7 |
| Placebo | Serum Concentration of Tezepelumab | Week 2 | 20.1 µg/mL | Standard Deviation 6.93 |
| Placebo | Serum Concentration of Tezepelumab | Week 24 | 6.95 µg/mL | Standard Deviation 5.65 |
| Placebo | Serum Concentration of Tezepelumab | Week 32 | 1.73 µg/mL | Standard Deviation 1.73 |
| Placebo | Serum Concentration of Tezepelumab | Week 8 | 21.2 µg/mL | Standard Deviation 8.54 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 32 | 11.0 µg/mL | Standard Deviation 10.8 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 1 | 0.00 µg/mL | Standard Deviation 0 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 2 | 41.3 µg/mL | Standard Deviation 12.4 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 4 | 71.3 µg/mL | Standard Deviation 20.8 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 8 | 101 µg/mL | Standard Deviation 30.5 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 12 | 123 µg/mL | Standard Deviation 44.1 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 16 | 136 µg/mL | Standard Deviation 43.4 |
| Omalizumab 300 mg SC Q4W | Serum Concentration of Tezepelumab | Week 24 | 37.3 µg/mL | Standard Deviation 21.1 |